Aytu BioScience Ownership

AYTU Stock  USD 1.29  0.04  3.20%   
30% of Aytu BioScience outstanding shares are owned by other corporate entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change.
 
Shares in Circulation  
First Issued
2009-03-31
Previous Quarter
M
Current Value
M
Avarage Shares Outstanding
5.1 M
Quarterly Volatility
6.6 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Dividends Paid is likely to drop to about 22 K in 2025. Dividend Paid And Capex Coverage Ratio is likely to gain to -646.47 in 2025. Common Stock Shares Outstanding is likely to gain to about 6.7 M in 2025, whereas Net Loss is likely to drop (16.1 M) in 2025.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aytu BioScience. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
For more information on how to buy Aytu Stock please use our How to Invest in Aytu BioScience guide.

Aytu Stock Ownership Analysis

About 31.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.26. Some equities with similar Price to Book (P/B) outperform the market in the long run. Aytu BioScience recorded a loss per share of 2.08. The entity last dividend was issued on the 9th of December 2020. The firm had 1:20 split on the 6th of January 2023. Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. Aytu Biopharma, Inc. was incorporated in 2015 and is headquartered in Englewood, Colorado. Aytu Biopharma operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 164 people. For more info on Aytu BioScience please contact Joshua Disbrow at (720) 437-6580 or go to https://aytubio.com.
Besides selling stocks to institutional investors, Aytu BioScience also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Aytu BioScience's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Aytu BioScience's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.

Aytu BioScience Quarterly Liabilities And Stockholders Equity

116.23 Million

Roughly 3.0% of Aytu BioScience are currently held by insiders. Unlike Aytu BioScience's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Aytu BioScience's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Aytu BioScience's insider trades

Aytu Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Aytu BioScience is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Aytu BioScience backward and forwards among themselves. Aytu BioScience's institutional investor refers to the entity that pools money to purchase Aytu BioScience's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Tower Research Capital Llc2024-12-31
2.6 K
Ubs Group Ag2024-12-31
1.5 K
Jpmorgan Chase & Co2024-09-30
626
Advisor Group Holdings, Inc.2024-12-31
300
Morgan Stanley - Brokerage Accounts2024-12-31
290
Wells Fargo & Co2024-12-31
124
Bank Of America Corp2024-12-31
100.0
Atlantic Trust Group, Llc2024-09-30
83.0
Sbi Securities Co Ltd2024-12-31
61.0
Nantahala Capital Management, Llc2024-12-31
1.1 M
Stonepine Capital Management Llc2024-12-31
407.5 K
Note, although Aytu BioScience's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Aytu BioScience Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Aytu BioScience insiders, such as employees or executives, is commonly permitted as long as it does not rely on Aytu BioScience's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Aytu BioScience insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Aytu BioScience Outstanding Bonds

Aytu BioScience issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Aytu BioScience uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Aytu bonds can be classified according to their maturity, which is the date when Aytu BioScience has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Aytu Stock Analysis

When running Aytu BioScience's price analysis, check to measure Aytu BioScience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aytu BioScience is operating at the current time. Most of Aytu BioScience's value examination focuses on studying past and present price action to predict the probability of Aytu BioScience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aytu BioScience's price. Additionally, you may evaluate how the addition of Aytu BioScience to your portfolios can decrease your overall portfolio volatility.